Microbial biotransformation – an important tool for the study of drug metabolism

References

• Abourashed EA, Clark AM, Hufford CD. (1999). Microbial models of mammalian metabolism of xenobiotics: an updated review. Curr Med Chem 6:359–74.
   PubMed Web of Science ®Google Scholar
• Biftu T, Colletti SL, Hagmann WK, et al. (2015). Antidiabetic tricyclic compounds. PCT Int. Appl., WO 2015/051496 16.04.2015.
   Google Scholar
• Boer J, Young-Sciame R, Lee F, et al. (2016). Roles of UGT, P450, and gut microbiota in the metabolism of epacadostat in humans. Drug Metab Dispos 44:1668–74.
   PubMed Web of Science ®Google Scholar
• Cannell RJP, Knaggs AR, Dawson MJ, et al. (1995). Microbial biotransformation of the angiotensin II antagonist GR117289 by Streptomyces rimosus to identify a mammalian metabolite. Drug Metab Dispos 23:724–9.
   PubMed Web of Science ®Google Scholar
• Cid JM, Tresadern G, Duvey G, et al. (2014). Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem 57:6495–512.
   PubMed Web of Science ®Google Scholar
• Cusack KP, Koolman HF, Lange UE, et al. (2013). Emerging technologies for metabolite generation and structural diversification. Bioorg Med Chem Lett 23:5471–83.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Obach RS, Kang P, et al. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357–368.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. (2009). ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf.
   Google Scholar
• Fura A, Shu YZ, Zhu M, et al. (2004). Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. J Med Chem 47:4339–4351.
   PubMed Web of Science ®Google Scholar
• Geier M, Bachler T, Hanlon SP, et al. (2015). Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microb Cell Fact 14:82.
   PubMed Web of Science ®Google Scholar
• Griffiths DA, Best DJ, Jezequel SG. (1991). The screening of selected microorganisms for use as models of mammalian drug metabolism. Appl Microbiol Biotechnol 35:373–381.
   PubMed Web of Science ®Google Scholar
• Grinter TJ, Moldt P, Watjen F. (2008). PCT Int. Appl., 2008104584.
   Google Scholar
• Gul T, Krzek M, Permentier HP, et al. (2016). Microbial flavoprotein monooxygenases as mimics of mammalian flavin-containing monooxygenases for the enantioselective preparation of drug metabolites. Drug Metab Dispos 44:1270–1276.
   PubMed Web of Science ®Google Scholar
• Hyde AM, Liu Z, Kosjek B, et al. (2016). Synthesis of the GPR40 partial agonist MK-8666 through a kinetically controlled dynamic enzymatic ketone reduction. Org Lett 18:5888–5891.
   PubMed Web of Science ®Google Scholar
• Jaworski TJ, Sardessai MS, Aravagiri M, et al. (1993). Synthesis of the N-oxides of phenothiazine antipsychotic agents. J Pharm Sci 82:330–333.
   PubMed Web of Science ®Google Scholar
• Lamb DC, Waterman MR, Zhao B. (2013). Streptomyces cytochromes P450: applications in drug metabolism. Expert Opin Drug Metab Toxicol 9:1279–1294.
   PubMed Web of Science ®Google Scholar
• Lassila T, Hokkanen J, Aatsinki SM, et al. (2015). Toxicity of carboxylic acid-containing drugs: the role of acyl migration and CoA conjugation investigated. Chem Res Toxicol. 28:2292–2303.
   PubMed Web of Science ®Google Scholar
• Li A, Yuan CC, Chow D, et al. (2011). Synthesis and Evaluation of the Metabolites of AMG 221, a Clinical Candidate for the Treatment of Type 2 Diabetes. ACS Med Chem Lett 2:824–7.
   PubMed Web of Science ®Google Scholar
• Li W, Josephs JL, Skiles GL, Humphreys WG. (2008). Metabolite generation via microbial biotransformations with Actinomycetes: rapid screening for active strains and biosynthesis of important human metabolites of two development-stage compounds, 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101) and dasatinib. Drug Metab Dispos 36:721–730.
   PubMed Web of Science ®Google Scholar
• Mali’n TJ, Weidolf L, Castagnoli N, Jr, Jurva U. (2010). P450-catalyzed vs. electrochemical oxidation of haloperidol studied by ultra-performance liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 24:1231–1240.
   PubMed Web of Science ®Google Scholar
• Mamidi RN, Cuyckens F, Chen J, et al. (2014). Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. Drug Metab Dispos 42:903–916.
   PubMed Web of Science ®Google Scholar
• Mansuy D. (2007). A brief history of the contribution of metalloporphyrin models to cytochrome P450 chemistry and oxidation catalysis. C R Chim 10:392–413.
   Web of Science ®Google Scholar
• Martin IJ, Lewis RJ, Bonnert RV, et al. (2003). NMR identification of an S-linked glucuronide of a triazole thione formed in vitro. Drug Metab Dispos 31:694–696.
   PubMed Web of Science ®Google Scholar
• Osorio-Lozada AS, Surapaneni S, Skiles GL, Subramanian R. (2008). Biosynthesis of drug metabolites using microbes in hollow fiber cartridge reactors: case study of diclofenac metabolism by Actinoplanes species. Drug Metab Dispos 36:234–240.
   PubMed Web of Science ®Google Scholar
• Piska K, Żelaszczyk D, Jamrozik M, et al. (2016). Cunninghamella biotransformation-similarities to human drug metabolism and its relevance for the drug discovery process. Curr Drug Metab 17:107–117.
   PubMed Web of Science ®Google Scholar
• Sawamura R, Okudaira N, Watanabe K, et al. (2010). Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos 38:1857–1864.
   PubMed Web of Science ®Google Scholar
• Schocken M. (1997). Microbial synthesis of agrochemical metabolites. J Ind Microbiol Biotechnol 19:392–400.
   Web of Science ®Google Scholar
• Singh J, Caers I, Daly E, Drevets WC. (2016). Methods and compositions comprising esketamine for treating depression. PCT Int. Appl., WO 2016187491 A1 20161124.
   Google Scholar
• Smith RV, Rosazza JP. (1974). Microbial models of mammalian metabolism. Aromatic hydroxylation. Arch Biochem Biophys 161:551–558.
   PubMed Web of Science ®Google Scholar
• Smith RV, Rosazza JP. (1975). Microbial models of mammalian metabolism. J Pharm Sci 64:1737–1759.
   PubMed Web of Science ®Google Scholar
• Steele J, de Riso A, Williams H, et al. (2018). Human metabolites of bosentan produced by enzymes in Hypha’s Polycyps™ cytochrome P450 kit. Drug Metab Pharm 33:S32.
   Web of Science ®Google Scholar
• Stepan AF, Tran TP, Helal CJ, et al. (2018). Late-stage microsomal oxidation reduces drug-drug interaction and identifies phosphodiesterase 2A inhibitor PF-06815189. ACS Med Chem Lett 9:68–72.
   PubMed Web of Science ®Google Scholar
• Swanson HI. (2015). Drug metabolism by the host and gut microbiota: a partnership or rivalry? Drug Metab Dispos 43:1499–1504.
   PubMed Web of Science ®Google Scholar
• United States, Food and Drug Administration Center for Drug Evaluation and Research. (2016). Safety testing of drug metabolites, guidance for industry. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf.
   Google Scholar
• Wilson ID, Nicholson JK. (2017). Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res 179:204–222.
   PubMed Web of Science ®Google Scholar
• Yasuhara A, Akiba-Goto M, Fujishiro K, et al. (2002). Production of aldehyde oxidases by microorganisms and their enzymatic properties. J Biosci Bioeng 94:124–129.
   PubMed Web of Science ®Google Scholar
• Zhang DL, Yang YF, Leakey JEA, Cerniglia CE. (1996). Phase I and phase II enzymes produced by Cunninghamella elegans for the metabolism of xenobiotics. FEMS Microbiol Lett 138:221–226.
   PubMed Web of Science ®Google Scholar
• Zhang T, Liu Y, Yang X, et al. (2016). Definitive metabolite identification coupled with automated ligand identification system (ALIS) technology: a novel approach to uncover structure − activity relationships and guide drug design in a factor IXa inhibitor program. J Med Chem 59:1818–1829.
   PubMed Web of Science ®Google Scholar